First presentation at AAD meeting of four-year Bimzelx (bimekizumab-bkzx) data showed long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis.- UCB
UCB, a global biopharmaceutical company, announced that the first presentations of Bimzelx (bimekizumab-bkzx) four-year efficacy and safety data in the treatment of adults with moderate to severe plaque psoriasis are being shared this week at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, U.S., March 8–12.